Literature DB >> 9508349

Paradoxical haemolysis in a patient with cold agglutinin disease.

E Ulvestad1.   

Abstract

A patient with classical cold agglutinin disease initially experienced haemolytic episodes during cold exposure. However, with advancing disease cold-induced haemolysis ceased and was substituted with a haemolytic disposition at elevated body temperatures. To investigate this paradoxical development of disease manifestations, we performed a clinical and immunological study. Our results indicate that the patient's complement system became exhausted during the later phase of his disease, probably due to continual consumption of complement components. Initially, the patient had slightly decreased C4 concentrations and moderately reduced total haemolytic activity (CH50). Later C4 fell to undetectable levels and CH50 declined to zero. The increased haemolytic activity experienced during febrile episodes is probably due to a cold agglutinin with a high thermal amplitude, combined with enhanced synthesis of complement molecules during the acute phase response. Although C4 concentrations never increased to detectable levels during infections or inflammations an acute phase reaction was determined each time, as evidenced by increased concentrations of CRP. By reconstituting the patient's serum with active complement from donor serum or plasma, increased haemolytic activity was observed. These results indicate that some patients with cold agglutinin disease may experience deleterious haemolytic consequences if transfused with plasma-containing blood products.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508349     DOI: 10.1111/j.1600-0609.1998.tb01004.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Lessons of the month 1: Polytrauma in a geriatric patient resulting in reactivation of cytomegalovirus infection and secondary cold agglutinin disease-induced haemolytic anaemia.

Authors:  Thomas Stockdale; Tom Hosack; Cameron Griffiths; Amit Kj Mandal; Constantinos G Missouris
Journal:  Clin Med (Lond)       Date:  2020-06-17       Impact factor: 2.659

2.  Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.

Authors:  Eirik Tjønnfjord; Øystein A Vengen; Sigbjørn Berentsen; Geir Erland Tjønnfjord
Journal:  BMJ Case Rep       Date:  2017-05-09

Review 3.  Cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.

Authors:  Sigbjørn Berentsen; Tatjana Sundic
Journal:  Biomed Res Int       Date:  2015-01-29       Impact factor: 3.411

5.  Evidence Suggesting Complement Activation and Haemolysis at Core Temperature in Patients with Cold Autoimmune Haemolytic Anaemia.

Authors:  Thilo Bartolmäs; Salih Yürek; Abdelwahab Hassan Ahmed Balola; Beate Mayer; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2015-08-04       Impact factor: 3.747

Review 6.  Role of Complement in Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Transfus Med Hemother       Date:  2015-09-07       Impact factor: 3.747

Review 7.  New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

Review 8.  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Authors:  Sigbjørn Berentsen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Hematology       Date:  2007-10       Impact factor: 2.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.